

Title: UARK 2008-02, TOTAL THERAPY 5 – A Phase II Trial for High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by applying Non-Host-Exhausting and Timely Dose-Reduced MEL-80+VRD-PACE Tandem Transplants with Interspersed MEL-20-VTD-PACE and alternating V-RD AND M-RD Maintenance

Sponsor: UAMS/MIRT

Co-PI: Yazan Alsayed, MD
Mauricio Pineda-Roman, MD

Phase: II

Purpose: This study has the following specific goals:

- To find out if giving multi-agent chemotherapy in lower and more frequent doses to make the timely delivery of chemotherapy cycles possible, will result in better treatment outcomes
- To find out if changing the way the drugs are given during the transplant phase will also result in fewer side effects, while still being effective
- To find out if giving treatment between transplants (called “inter-transplant therapy”) will prevent the myeloma from re-growing between transplants

Eligibility: You are being asked to take part in this research study because you have high-risk multiple myeloma that requires treatment. About 90 research participants, male or female, age 18 and older, regardless of race or ethnicity, will take part in this study.

Treatment: The treatment on this study is divided into 5 phases;

1. Induction chemotherapy and stem cell collection
2. Transplant #1
3. Inter-Transplants #1 and #2
4. Transplant #2
5. Maintenance therapy

Contact: Nathan Petty pettynathanm@uams.edu (501) 526-6990 ext. 2435